Harvard Bioscience
HBIO
68 hedge funds and large institutions have $8.39M invested in Harvard Bioscience in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 37 closing their positions.
510% more call options, than puts
Call options by funds: $61K | Put options by funds: $10K
1.54% less ownership
Funds ownership: 5.82% → 4.28% (-1.5%)
25% less funds holding
Funds holding: 91 → 68 (-23)
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
42% less capital invested
Capital invested by funds: $14.5M → $8.39M (-$6.12M)
62% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 37
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$321K |
| 2 |
Millennium Management
New York
|
+$267K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$58K |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$52.3K |
| 5 |
AE
AMH Equity
Great Neck,
New York
|
+$50.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$1.01M |
| 2 |
BlackRock
New York
|
-$713K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$627K |
| 4 |
State Street
Boston,
Massachusetts
|
-$249K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$202K |
HBIO Hedge Fund Activity: Q2 2025 in Review
68 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2025, worth a combined $8.39M — down 42% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of HBIO and 14 opened new positions — a net loss of 23 holders — while 27 trimmed existing stakes and 19 added.
The largest buyer was UBS Group, adding an estimated $321K. The largest seller was Royce & Associates, exiting entirely with an estimated $1.01M sold.
- 68 institutional investors held Harvard Bioscience (HBIO) as of Q2 2025, down from 91 in Q1 2025.
- Funds reported $8.39M of Harvard Bioscience stock for Q2 2025, down 42% quarter-over-quarter.
- 14 funds opened new Harvard Bioscience positions in Q2 2025 and 37 closed out, a net change of -23 holders.
- The largest Harvard Bioscience buyer in Q2 2025 was UBS Group, an estimated $321K added.
- The largest Harvard Bioscience seller in Q2 2025 was Royce & Associates, an estimated $1.01M sold.
Based on aggregated 13F filings for Q2 2025.